CagriSema
Also known as: cagrisema
CagriSema is Novo Nordisk's investigational once-weekly fixed-dose co-formulation of cagrilintide 2.4 mg (long-acting amylin analog) with semaglutide 2.4 mg (GLP-1 receptor agonist) for chronic weight management. Unlike the other grey-market blends, it has a proper Phase 3 clinical program. Novo Nordisk filed an FDA NDA in December 2025; as of April 2026 it is under FDA review and not yet approved.
Who's worth your money for CagriSema
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (82) of 1 scored sellers
$65.99 · 10mg
Average price
$12.67/mg
Sellers
18
45-day trend
+22.7%
11 of 18 sellers have a current price· 10 stale hidden
- Modern Research Peptides82
✓ verified at source · just now
$6.60/mg -47.9% vs avg$65.99
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch CagriSema
Get one email when the market actually moves — no newsletter, no noise.
About CagriSema
CAS
—
Molecular formula
—
Typical dose range
2.4 mg/week cagrilintide + 2.4 mg/week semaglutide, subcutaneous once-weekly; dose-escalation starting at 0.16 mg/week cagrilintide escalated over 16 weeks
Half-life
Cagrilintide ~184 hours (~7.7 days); semaglutide ~158 hours (~6.6 days)
COAs for CagriSema
7 third-party tests across 5 vendors. Each card links to the full report.
For
CagriSema
by Simple Peptide· batch 02-21101-02905-P
For
CagriSema
by Simple Peptide· batch CGSM09032025-J
For
CagriSema
by Profound Aminos· batch 2025-04-31
For
CagriSema
by Hydro Research Peptides· batch 2024-08-05
For
CagriSema
by Profound Aminos· batch cmojb7ss001e3kirxyi4q8sbq
Purity not on file
For
Cagrisema
by Peptide Crafters· batch PC-J2-CS10
Purity not on file
For
Cariintide/Semaglutide
by Certified Peptides· batch 251227CS53
20 citations indexed for CagriSema
review · 2026
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials
To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
Study · 2026
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Background Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
Study · 2026
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1
Aims To assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity.
review · 2026
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis
Background Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.
Study · 2026
Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
review · 2026
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis
Background Long-acting amylin-based therapies (ABTs) are emerging anti-obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and rank agents and doses within a network meta-analysis (NMA) framew…